Device Trial Radar · NCT05131178
Post-operative Cesarean Trial of Pain Control
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 7, 2021
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- University of Colorado, DenverAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Avanos Medical; Children's Hospital Colorado; Colorado Fetal Care Center
- First posted
- Nov 23, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study plans to learn more about postoperative pain management after cesarean deliveries (C-sections). As a part of standard of care, the Children's Hospital Colorado's Colorado Fetal Care Center (CFCC) follows the standard Enhanced Recovery After Cesarean (ERAC) guidelines to manage pain following C-section delivery. In addition, the CFCC uses an FDA approved medical device called the ON-Q ® Pump, which continuously delivers local anesthetic medication to control pain in the area of your procedure. The local anesthetic used is bupivacaine, which is FDA approved for use to control local pain after C-sections. The CFCC has found a significant reduction in opioid use after adopting both of these procedures. The study aims to determine if the ERAC protocol or ON-Q ® Pump continuous infusion is responsible for lower opioid use by comparing bupivacaine (treatment) versus saline (placebo) groups.
Conditions
- Post-operative Pain
- Cesarean Section
Interventions
ON-Q Pump® with continuous infusion of bupivacaineDevice
270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
ON-Q Pump® with continuous infusion of salineDevice
270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total postoperative opioid useTime frame: Post-operative day 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.